Recce Pharma
Level 34, 50 Bridge Street
AMP Centre
Sydney
New South Wales
2000
Australia
Tel: 61-2-8216-0768
Website: http://www.recce.com.au/
Email: peter.williams@recce.com.au
About Recce Pharma
Recce Ltd is a world-leader in synthetic-polymer antibiotics. The RECCE® antibiotics have been synthesized by an extremely economic method. RECCE® antibiotics have shown in laboratory tests that they have continued activity against bacteria, including superbugs, even after repeated use. Recce is positioned to achieve milestones in both pre-clinical trials for FDA purposes, and the development of the manufacture of RECCE® 327.
YEAR FOUNDED:
2007
LEADERSHIP:
Founder: Graham JH Melrose
CFO: Peter Williams
CLINICAL TRIAL:
61 articles with Recce Pharma
-
Recce Pharmaceuticals Appoints Philip Sutton, Ph.D., as Vice President of Translational Sciences
7/12/2022
Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) (the Company), the company developing a new class of synthetic anti-infectives, is pleased to announce the appointment of Philip Sutton, Ph.D., as Vice President of Translational Sciences.
-
Olink said the measurement of proteins at "population scale" provides the ability to improve the understanding of underlying mechanisms of diseases.
-
A roundup of last week's top clinical trial announcements and news, including updates from Pfizer, BioNTech, Ocugen and more.
-
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in Hong Kong for RECCE® Anti-Infectives
4/12/2022
Recce Pharmaceuticals Limited is pleased to announce the Intellectual Property Department of the Hong Kong Special Administrative Region has granted patent family three, “Anti-Virus Agent and Method for Treatment of Viral Infection,” furthering marketing and manufacturing exclusivity to February 2037.
-
It was a particularly busy week for clinical trial announcements. Let's take a look.
-
Recce Pharmaceuticals Announces Positive Safety Data from Fourth Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
3/30/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort four at 1,000mg (twenty-fold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among 10 healthy male subjects.
-
Recce Pharmaceuticals Receives Research and Development (R&D) Incentive Rebate
3/29/2022
Recce Pharmaceuticals Ltd, the Company developing a new class of synthetic anti-infectives, is pleased to announce it has received a Research and Development Tax Incentive rebate of A$3,084,955.19 from the Australian Tax Office for the year ending June 30, 2021.
-
Recce Pharmaceuticals Announces Safety Committee Clears Next Dose in Phase I Study of RECCE® 327
3/8/2022
Recce Pharmaceuticals Ltd is pleased to report an Independent Safety Committee data review of 10 healthy human subjects intravenously dosed in the Phase I intravenous clinical trial of RECCE® 327, demonstrating a good safety and tolerability profile – unanimously recommending cohort four to commence.
-
The FDA places holds, companies receive clearance for new studies and Pharma giants release new data in last week's clinical trial news.
-
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
-
Recce Pharmaceuticals Announces Positive Safety Data from Third Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
2/8/2022
Recce Pharmaceuticals Ltd is pleased to report Phase I intravenous (IV) clinical trial of RECCE® 327 (R327) cohort three at 500mg (tenfold increase on cohort one 50mg dose), indicating a good safety and tolerability profile among seven healthy male subjects.
-
Recce Pharmaceuticals Announces Positive Safety Data from Second Cohort of Phase I Clinical Trial Evaluating Healthy Subjects Intravenously Dosed with RECCE® 327
1/19/2022
Recce Pharmaceuticals Ltd is pleased to report further positive data from its Phase I intravenous (IV) clinical trial of RECCE® 327 (R327).
-
A Perfect Storm of Superbugs
1/17/2022
To alleviate the problem of antibiotic-resistant bacteria, or superbugs, several biotechnology companies are developing different strategies to target and kill these microorganisms. -
Recce Pharmaceuticals Announces Anti-Viral Patent Granted in China for RECCE® Anti-Infectives
7/21/2021
Recce Pharmaceuticals Ltd is pleased to announce the Chinese Patent Office has granted Patent Family 3 “ Anti-Virus Agent and Method for Treatment Of Viral Infections ”
-
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Demonstrates Outstanding Efficacy Against Necrotizing Fasciitis ‘Flesh-Eating’ Bacteria
7/20/2021
RECCE is pleased to announce positive efficacy of RECCE® 327 (R327) against Clostridium perfringens (C. perfringens) and Streptococcus pyogenes (S. pyogenes), two main strains of bacteria associated with necrotizing fasciitis, also known as ‘flesh-eating’ disease – a life-threatening bacterial infection with a mortality rate of up to 80%.
-
Recce Pharmaceuticals to Present at World Microbe Forum
6/21/2021
Recce Pharmaceuticals Ltd has accepted an invitation to present at the World Microbe Forum following confirmation to publish a recent abstract in the 2021 program.
-
Recce Pharmaceuticals Announces Lead Synthetic Anti-infective RECCE® 327 Progresses to Stage 2 of SARS-CoV-2 Antiviral Screening Program at CSIRO
5/20/2021
Further study completed at the Doherty Institute as part of SARS-CoV-2 Antiviral Screening Program calculates IC50 of RECCE® 327 (R327) to be 2,046 PPM and the CC50 for R327 to be 5108 PPM
-
Recce Pharmaceuticals Announces Positive Data on Bactericidal Activity of RECCE® 327 Against All Six ESKAPE Pathogens
5/4/2021
More than 99.9% effective against full suite of ESKAPE pathogens, within hours of exposure to RECCE® 327 (R327) in independent bacterial efficacy studies
-
Recce Pharmaceuticals Dual Lists on Frankfurt Stock Exchange - Mar 09, 2021
3/9/2021
Recce Pharmaceuticals Ltd, the Company developing new classes of synthetic anti-infectives is pleased to announce the Company’s shares are now Dual Listed on the Frankfurt Stock Exchange